Today
-3.96%
5 Days
-6.05%
1 Month
-6.39%
6 Months
-5.33%
Year to Date
+0.64%
1 Year
-0.45%
• Regulatory restrictions on nicotine products challenge British American Tobacco's New Categories revenue growth projections. • Higher interest rates and inflation reduce the appeal of the company's dividend-focused stock. • Market share erosion in U.S. vapor markets contributes to increased selling pressure and volatility.
• Philip Morris International surpassed quarterly earnings estimates, driving stock appreciation. • Revenue growth is fueled by strong demand for smoke-free products. • Management raised full-year guidance, bolstered by successful diversification into reduced-risk alternatives.
• BTI reiterated 2026 outlook at the lower end of guidance. • Regulatory uncertainties impact BTI, especially FDA actions. • BTI's MACD indicates a sell signal, RSI is neutral.
• UK generational tobacco ban progressing towards law. • US FDA guidance tightens flavored e-cigarette regulations. • Zambia tobacco control bill signals global regulatory headwinds.
• British American Tobacco stock price declined due to subsidiary's poor results. • Subsidiary reported lower dividend, Q4 loss, and reduced full-year earnings. • U.S. vaping regulations and analyst ratings contribute to market caution.
• British American Tobacco reaffirmed 2026 guidance and CAGNY conference outlook. • Company expanded cannabis investment via Organigram Global acquisition support. • Stock benefited from positive analyst ratings and robust dividend policy.


| Shareholders | Proportion |
|---|---|
| Capital International Investors | 2.97% |
| GQG Partners, LLC | 1.28% |
| Fidelity Management & Research Company LLC | 1.21% |
| Capital Research Global Investors | 1.03% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 10.56% |
| Investment Advisor/Hedge Fund | 1.84% |
| Hedge Fund | 0.88% |
| Research Firm | 0.65% |
Related Instruments
Popular Instruments